zoledronic acid + Any oral bisphosphonates marketed in Canada
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Menopausal Osteoporosis
Conditions
Post-Menopausal Osteoporosis
Trial Timeline
Nov 1, 2008 → Apr 1, 2014
NCT ID
NCT00984893About zoledronic acid + Any oral bisphosphonates marketed in Canada
zoledronic acid + Any oral bisphosphonates marketed in Canada is a pre-clinical stage product being developed by Novartis for Post-Menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00984893. Target conditions include Post-Menopausal Osteoporosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00984893 | Pre-clinical | Completed |
Competing Products
19 competing products in Post-Menopausal Osteoporosis